612 related articles for article (PubMed ID: 11436112)
1. Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients.
Min CK; Eom KS; Lee S; Kim DW; Lee JW; Min WS; Kim CC
Bone Marrow Transplant; 2001 May; 27(9):999-1005. PubMed ID: 11436112
[TBL] [Abstract][Full Text] [Related]
2. Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation.
Elmaagacli AH; Beelen DW; Trenn G; Schmidt O; Nahler M; Schaefer UW
Bone Marrow Transplant; 1999 Apr; 23(8):771-7. PubMed ID: 10231138
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
Glass B; Majolino I; Dreger P; Scimè R; Santoro A; Vasta S; Suttorp M; Haferlach T; Schmitz N
Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054
[TBL] [Abstract][Full Text] [Related]
4. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
[TBL] [Abstract][Full Text] [Related]
5. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
[TBL] [Abstract][Full Text] [Related]
7. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.
de Lima M; Bonamino M; Vasconcelos Z; Colares M; Diamond H; Zalcberg I; Tavares R; Lerner D; Byington R; Bouzas L; da Matta J; Andrade C; Carvalho L; Pires V; Barone B; Maciel C; Tabak D
Bone Marrow Transplant; 2001 Jan; 27(1):73-8. PubMed ID: 11244440
[TBL] [Abstract][Full Text] [Related]
9. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S
Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome after allogeneic bone marrow transplantation for hematological malignancies with non-remission status. Results of a single-center study of 24 patients.
Tabata M; Satake A; Okura N; Yamazaki Y; Toda A; Nishioka K; Tanaka H; Chin M; Itsukuma T; Yamaguchi M; Misawa M; Kai S; Hara H
Ann Hematol; 2002 Oct; 81(10):582-7. PubMed ID: 12424540
[TBL] [Abstract][Full Text] [Related]
12. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
[TBL] [Abstract][Full Text] [Related]
13. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
14. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant.
de Lima M; van Besien K; Gajewski J; Khouri I; Andersson B; Korbling M; Champlin R; Giralt S
Bone Marrow Transplant; 2000 Aug; 26(3):333-8. PubMed ID: 10967575
[TBL] [Abstract][Full Text] [Related]
15. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B
Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
[TBL] [Abstract][Full Text] [Related]
16. Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation.
Siegert W; Beyer J; Kingreen D; Blasczyk R; Baurmann H; Schwella N; Schleicher J; Kirsch A; Huhn D
Bone Marrow Transplant; 1998 Sep; 22(6):579-83. PubMed ID: 9758347
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan Society for Hematopoietic Cell Transplantation Working Party.
Kataoka I; Kami M; Takahashi S; Kodera Y; Miyawaki S; Hirabayashi N; Okamoto S; Matsumoto N; Miyazaki Y; Morishita Y; Asai O; Maruta A; Yoshida T; Imamura M; Hamajima N; Matsuo K; Harada M; Mineishi S;
Bone Marrow Transplant; 2004 Oct; 34(8):711-9. PubMed ID: 15361916
[TBL] [Abstract][Full Text] [Related]
18. Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant.
Blau IW; Basara N; Bischoff M; Günzelmann S; Römer E; Kirsten D; Schmetzer B; Kiehl MG; Fauser AA
Bone Marrow Transplant; 2000 Jan; 25(1):41-5. PubMed ID: 10654013
[TBL] [Abstract][Full Text] [Related]
19. Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation.
Jabro G; Koc Y; Boyle T; Schenkein DP; Ravalese J; Wazer D; Miller KB
Biol Blood Marrow Transplant; 1999; 5(3):173-9. PubMed ID: 10392963
[TBL] [Abstract][Full Text] [Related]
20. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
Zuffa E; Bandini G; Bonini A; Santucci MA; Martinelli G; Rosti G; Testoni N; Zaccaria A; Tura S
Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
